Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New German Reimbursement Process Splits Opinion Ahead Of First Assessments

Executive Summary

Several drug firms – including, most vociferously, Eli Lilly & Co. – have already concluded that Germany's tough new reimbursement laws are the root of much evil. But others are taking more of a wait-and-see approach to the new system, which demands that companies provide compelling proof, upfront, of the added benefit of their drugs over existing therapies.

You may also be interested in...



German HTA Blueprint Could Be Imposed On Greece

Germany’s role in preparing a health reform agreement between Greece and the World Health Organization may lead to a G-BA/IQWiG-style HTA process being introduced in the Hellenic Republic.

Emerging Markets, U.S. Provide Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher

Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.

U.S. Provides Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher

Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.

Related Content

Topics

UsernamePublicRestriction

Register

PS053624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel